Janssen Research & Development, Llc

This study looks at how well the body absorbs different versions of two prostate cancer drugs, niraparib and abiraterone acetate, in men with advanced prostate cancer that no longer responds to hormone therapy. About 136 men will take the drugs in different forms and sequences to…

This early-stage study tests a new drug, teclistamab, in about 300 people with multiple myeloma (a type of blood cancer) that has returned or stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. Teclistamab works by helping t…

This study is testing two drugs, ustekinumab and guselkumab, in 50 children with active juvenile psoriatic arthritis (a type of arthritis that also affects the skin). The goal is to see how well the drugs work, how they move through the body, and if they are safe. Participants re…

This study tests a drug called guselkumab in people with active psoriatic arthritis who did not get better or could not tolerate a previous treatment (anti-TNF therapy). The goal is to see if guselkumab can reduce joint pain and swelling. About 453 adults will receive either guse…

This early-phase study tests the drug apalutamide in Chinese men whose prostate cancer has spread and no longer responds to hormone therapy. The main goals are to check how the drug moves through the body and to monitor any side effects. Nineteen participants will take a daily 24…

This study tests a new drug called teclistamab in people with multiple myeloma that has come back or stopped responding to other treatments. The drug is designed to help the immune system attack cancer cells. About 194 participants will receive the drug to see how well it shrinks…

This study tests a new drug called teclistamab against two standard treatment combinations (PVd or Kd) in about 614 people with multiple myeloma that has come back or not responded after 1 to 3 prior therapies. The goal is to see if teclistamab can better delay cancer progression…

This study tests a drug called guselkumab in about 1,400 people with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut lining better than a placebo or another active drug. Participants receive injections and are monitored for up to …

This large study compares a new oral blood thinner, milvexian, to the standard drug apixaban in about 20,000 adults with atrial fibrillation (an irregular heartbeat). The goal is to see if milvexian works at least as well at preventing strokes and blood clots. Participants will t…

This early-stage study tests a new drug called JNJ-78278343 for advanced prostate cancer that has spread. The drug works by redirecting the body's immune T-cells to attack cancer cells. The study involves 216 men and aims to find the safest and most effective dose, while monitori…

This early-stage study tests a combination of two types of drugs—bispecific antibodies (talquetamab or teclistamab) and a PD-1 inhibitor—in about 74 people whose multiple myeloma has returned or stopped responding to prior treatments. The main goal is to find safe doses and check…

This study follows 97 people with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss, to see if a one-time gene therapy is safe and helps preserve sight over time. Participants received an injection of a modified virus carrying a working copy of the RPGR…

This study tests a drug called guselkumab in about 1064 people with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. The goal is to see if the drug can reduce symptoms like diarrhea and bleeding and help heal the gut lining. Participants recei…

This study tests a combination of drugs (daratumumab plus chemotherapy) in people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs, especially the heart. The main goals are to check heart safety and measure drug levels in different racial …

This study tests a drug called guselkumab for children and teens (ages 6 to 17) with chronic plaque psoriasis, a skin condition causing red, scaly patches. About 120 participants will receive either the study drug, a placebo, or an active comparator to see if it safely clears or …

This study looks at the long-term safety of ustekinumab in children aged 2 to under 18 who have Crohn's disease, ulcerative colitis, or psoriatic arthritis. Participants must have already completed a prior study and shown benefit from the drug. The main goal is to track side effe…

This study tests an oral drug called JNJ-77242113 in 684 adults with moderate to severe plaque psoriasis. The goal is to see if it can clear or nearly clear skin patches compared to a placebo. Participants may stop and restart treatment to see how well it works over time.

This study tests combinations of the drug daratumumab with two other therapies (talquetamab and teclistamab) in people with multiple myeloma, a type of blood cancer. The goal is to find the safest and most effective doses and to monitor side effects. About 290 adults who have alr…

This study tests whether adding the drug talquetamab to standard treatments can help people with multiple myeloma (a blood cancer) whose cancer has returned or stopped responding to prior therapy. About 864 participants will receive one of three treatment combinations. The main g…

This early-stage study tests a new drug (JNJ-87801493) combined with immune-activating therapies for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goals are to check safety and find the best dose. About 70 participants wil…

This study tests a combination of two drugs, amivantamab and capmatinib, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combination can shrink tumors. About 57 adults with specific genetic changes (MET mutation…

This study tests a new oral medication, JNJ-77242113, for people with plaque psoriasis affecting special areas like the scalp, genitals, palms, and soles. About 311 adults who need systemic treatment will receive either the drug or a placebo. The main goal is to see if the drug c…

This study is testing whether a new combination treatment can help people with muscle-invasive bladder cancer keep their bladder while controlling their cancer. It compares a new approach (TAR-200, a drug-releasing device placed in the bladder, plus an immunotherapy drug called c…

This study tests two experimental treatments—TAR-200 (a drug placed inside the bladder) and cetrelimab (an immunotherapy injection)—alone or together, in people with high-risk bladder cancer that came back after BCG therapy. Participants are those who cannot have or choose not to…

This study follows up to 120 people with different cancers (like leukemia, lymphoma, and solid tumors) who have already been treated in an earlier study. The main goal is to track serious side effects and other health issues over time. Participants continue their current treatmen…

This study tests an injected drug called guselkumab to see if it can put moderate to severe ulcerative colitis into remission. About 418 adults who haven't responded well to other treatments will receive either the drug or a placebo. The main goal is to check if symptoms like dia…

This early-phase study tests a new drug called ARX517, alone or with other prostate cancer treatments, in 183 men with metastatic prostate cancer that has spread. The main goal is to check the drug's safety and find the right dose. Participants must have confirmed prostate cancer…

This study tests an experimental drug called JNJ-77242113 (icotrokinra) for people with active psoriatic arthritis who have not tried biologic treatments before. About 552 adults will receive either the drug or a placebo to see if it reduces joint pain, swelling, and skin symptom…

This study tests different combinations of the drug niraparib with other treatments in 136 men whose prostate cancer has spread and no longer responds to hormone therapy. The goal is to find the safest dose and see if the combinations can shrink tumors or lower PSA levels. Partic…

This study tests a new treatment called JNJ-68284528, a CAR-T cell therapy, for people with multiple myeloma. The goal is to see if it can reduce cancer cells to undetectable levels (minimal residual disease negative). About 210 participants who have already tried other treatment…

This early-stage study tests an experimental drug, JNJ-80948543, that helps the body's immune T-cells attack cancer cells. It is for people with certain types of blood cancer (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have not responded to other treatments. The m…

This study tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) whose cancer has stopped responding to the drug osimertinib. About 776 p…

This program offers continued treatment with nipocalimab to people with warm autoimmune hemolytic anemia (wAIHA) who saw improvement in a previous study. Participants must have completed the earlier 28-week study and still be benefiting from the drug. The goal is to keep their co…

This study tests a gene therapy given to the second eye in people with X-linked retinitis pigmentosa, a genetic condition that causes progressive vision loss. Participants already received treatment in one eye in an earlier study. The goal is to check safety and whether vision ca…

This study tests an experimental drug, JNJ-77242113, in 774 adults with moderate to severe plaque psoriasis. It compares the drug to a placebo and another approved treatment (deucravacitinib) to see how well it clears skin and reduces symptoms. The goal is to find a new oral opti…

This study tests the drug apalutamide in Chinese men with a type of prostate cancer that has stopped responding to hormone therapy but hasn't spread. The goal is to see if it can delay a rise in PSA levels, a key sign of cancer progression. Participants will receive either apalut…

This program gives talquetamab, a single-drug treatment, to people with multiple myeloma that has returned or is hard to treat. Participants must have tried all available treatments and cannot join a clinical trial. The goal is to provide access to this therapy before it is fully…

This study tests a new treatment called cilta-cel, which uses a patient's own immune cells to fight multiple myeloma that has come back after previous treatments. About 419 adults with relapsed multiple myeloma will either receive cilta-cel or standard drug combinations. The main…

This study tests a combination of two drugs (TAR-200 and cetrelimab) for people with a type of bladder cancer that has grown into the muscle wall. Participants are scheduled to have their bladder removed and cannot or choose not to have standard chemotherapy before surgery. The m…

This study tests whether combining two drugs (guselkumab and golimumab) works better than either drug alone for people with moderate to severe ulcerative colitis. About 577 adults who haven't responded well to other advanced treatments will take part. The main goal is to see if m…

This phase 3 study tests whether adding daratumumab to a standard three-drug regimen (bortezomib, lenalidomide, dexamethasone) helps people with newly diagnosed multiple myeloma who are not planning a stem cell transplant. The goal is to see if the four-drug combination leads to …

This early-stage study tests a new drug called bleximenib combined with other leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 partici…

This early-stage study is testing a new treatment called JNJ-90009530 for adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The treatment uses a patient's own immune cells, which are modified in a lab to target and attack cancer…

This study tests a new way to give the drug amivantamab as a quick shot under the skin, instead of a long IV drip, for people with a certain type of advanced lung cancer. About 418 participants whose cancer has worsened after standard treatments will receive either the new shot o…

This study tests whether a new way of making teclistamab works as well as the current version in people with multiple myeloma that has come back or not responded to treatment. About 108 participants will receive either the old or new version, and researchers will measure drug lev…

This study tests whether a single infusion of cilta-cel (a CAR-T cell therapy) works better than standard maintenance drugs for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. About 743 participants will receive initial chemotherapy f…

This study tests whether a new combination of two drugs (teclistamab and daratumumab) works better than standard treatments for people with multiple myeloma that has returned or stopped responding to therapy. About 587 participants will receive either the new combo or one of two …

This study tests whether guselkumab can reduce spine-related symptoms in people with active psoriatic arthritis who have not used biologic drugs before. About 411 participants will receive either guselkumab or a placebo. The main goal is to see if the drug lowers disease activity…

This early-stage study tests if amivantamab, a drug that targets certain cancer cells, can be given as a shot under the skin instead of through an IV. It includes 158 adults with advanced solid tumors like lung or head and neck cancer. The main goals are to check safety, find the…

This early-stage study tests a new drug, JNJ-69086420, which is an antibody carrying a radioactive particle that targets a protein found on prostate cancer cells. The study involves about 144 men with advanced prostate cancer that has spread and no longer responds to hormone ther…

This study tests a combination of two treatments, ciltacabtagene autoleucel (a cell therapy) and talquetamab (a drug), in people with high-risk multiple myeloma. The main goal is to check safety, but researchers will also see how well the cancer responds. Only 11 participants are…

This study tests a drug called erdafitinib in people with advanced solid tumors that have certain changes in FGFR genes. The goal is to see if the drug can shrink tumors. The study includes both adults and children who have already tried other treatments or have no standard optio…

This study tests a new oral medication, JNJ-77242113, for people with moderate to severe plaque psoriasis. About 731 adults will receive either the new drug, a placebo, or an active comparator (deucravacitinib) to see how well it clears skin lesions and reduces redness, thickness…

This early-stage study tests the safety and best doses of teclistamab when combined with other cancer drugs for people with multiple myeloma, a type of blood cancer. About 140 participants who have already tried other treatments will receive different drug combinations. The goal …

This study tests different sequences of advanced cell and antibody therapies (Cilta-cel, Tal-D, Tec-D) after initial chemotherapy in 43 people with newly diagnosed multiple myeloma. The goal is to see if these combinations can achieve deep, lasting remission with no detectable ca…

This study tests a drug called guselkumab in about 1054 adults with active psoriatic arthritis (PsA) who haven't gotten enough relief from other treatments. The goal is to see if the drug can reduce joint pain and swelling and slow down joint damage seen on X-rays. Participants r…

This study tests a drug called guselkumab in 350 people with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut lining after 12 weeks of treatment. Participants must have tried other treatments without success. This is a phase 3 tria…

This study looks at men with advanced prostate cancer that still responds to hormone therapy. After 6 months of standard treatment (apalutamide plus continuous hormone therapy), those whose PSA levels dropped very low are randomly assigned to either continue or pause the hormone …

This phase 3 study tests whether a combination of two targeted drugs, ibrutinib and venetoclax, works better than standard chemotherapy plus an antibody for adults with chronic lymphocytic leukemia (CLL) who have not had prior treatment. The main goal is to see how long the disea…

This study was designed to test whether nipocalimab could help people with active lupus nephritis, a kidney condition caused by lupus. The trial planned to compare nipocalimab against a placebo in about 0 participants, but it was withdrawn before anyone enrolled. No results are a…

This program offers early access to TAR-200, an experimental treatment, for people with high-risk non-muscle invasive bladder cancer who have run out of other options. Participants must have tried all standard treatments and cannot join a clinical trial. The goal is to provide tr…

This study tests whether adding the drug niraparib to standard hormone therapy (abiraterone and prednisone) can delay cancer growth in men with metastatic prostate cancer that has specific gene mutations (HRR). About 700 participants received either the combination or standard th…

This study tests whether adding the drug niraparib to standard treatment (abiraterone and prednisone) can slow the growth of metastatic prostate cancer that no longer responds to hormone therapy. About 765 men with specific genetic changes took part. The main goal was to see how …

This study tests whether adding the drug amivantamab to standard chemotherapy helps people with a certain type of advanced lung cancer (EGFR Exon 20ins mutation) live longer without their cancer growing. About 308 participants received either the drug combo or chemo alone. The ma…

This program gives patients with multiple myeloma that has come back or stopped responding to other treatments access to talquetamab. It is for people who have no other options. The goal is to control the disease, not cure it.

This study tests whether giving dexamethasone, montelukast, or methotrexate before an amivantamab infusion can reduce or prevent infusion-related reactions in people with advanced non-small cell lung cancer. The trial enrolled 68 participants who had previously taken osimertinib.…